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ABSTRACT
In 2005, the combined pulmonary fibrosis and emphysema (CPFE) was first defined as a distinct entity, which comprised 
centrilobular or paraseptal emphysema in the upper pulmonary lobes, and fibrosis in the lower lobes accompanied by 
reduced diffused capacity of the lungs for carbon monoxide (DLCO). Recently, the fibrosis associated with the connective 
tissue disease was also included in the diagnosis of CPFE, although the exposure to tobacco, coal, welding, agrochemical 
compounds, and tire manufacturing are the most frequent causative agents. This entity characteristically presents 
reduced DLCO with preserved lung volumes and severe pulmonary hypertension, which is not observed in emphysema 
and fibrosis alone. We present the case of a 63-year-old woman with a history of heavy tobacco smoking abuse, who 
developed progressive dyspnea, severe pulmonary hypertension, and cor pulmonale over a 2-year period. She attended 
the emergency facility several times complaining of worsening dyspnea that was treated as decompensate chronic 
obstructive pulmonary disease (COPD). The imaging examination showed paraseptal emphysema in the upper pulmonary 
lobes and fibrosis in the middle and lower lobes. The echo Doppler cardiogram revealed the dilation of the right cardiac 
chambers and pulmonary hypertension, which was confirmed by pulmonary trunk artery pressure measurement by 
catheterization. During this period, she was progressively restricted to the minimal activities of daily life and dependent 
on caregivers. She was brought to the hospital neurologically obtunded, presenting anasarca, and respiratory failure, 
which led her to death. The autopsy showed signs of pulmonary hypertension and findings of fibrosis and emphysema 
in the histological examination of the lungs. The authors highlight the importance of the recognition of this entity in 
case of COPD associated with severe pulmonary hypertension of unknown cause. 
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CASE REPORT
A 63-year-old Caucasian woman sought the 
emergency department (ED) because of severe dyspnea 
during the last month, which had been worsening 
over the last 2 years. She was a heavy tobacco 
smoker (102 packs/year) since an early age and was 
irregularly following treatment for hypertension. 
In a 2-year period, she attended the ED five times 
complaining of dyspnea with the working diagnosis 
of decompensate chronic obstructive pulmonary 
disease (COPD) by respiratory infection. At her second 
emergency appointment, (specifically 18 months ago) 
she was submitted to a thoracic computed tomography 
(CT) that revealed signs of pulmonary hypertension 
characterized by the enlargement of the pulmonary 
trunk artery and its branches, dilation of the right 
cardiac chambers, and moderate pericardial effusion 
(Figure 1). The analysis of the pulmonary window 
showed a disease characterized predominantly by 
ground glass opacity, eventually with subpleural 
sparing in the lung bases associated with some 
areas of thin reticulated and traction bronchiectasis. 
No honeycomb cysts were found. These imaging 
features were consistent with non-specific interstitial 
pneumonia (Figure 2). Emphysema, predominantly 
of the paraseptal subtype, was observed in the 
upper lobes. Additionally, there was a discrete 
atheromatosis of the aorta, which was negligible in the 
coronary territory, and a mild splenomegaly. The echo 
Doppler cardiogram showed a normal left ventricular 
systolic function, but an estimated pulmonary artery 
pressure of 100 mmHg, which was confirmed with 
the right cardiac catheterization and pressures 
Figure 1. Chest CT mediastinal window, showing signs of pulmonary hypertension. A - Note the pulmonary trunk 
caliber is greater than the aorta; B - Dilation of the right cardiac chambers; C - Reflux of the contrast media into 
the dilated inferior vena cava and hepatic veins; D - Moderate pericardial effusion. A, B, and C = axial plane; 
D = sagittal plane.
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measurement. The stool examination (three samples) 
and rectal biopsy were negative for Schistosoma 
mansoni’s eggs; the pulmonary angiogram failed 
to demonstrate pulmonary thromboembolism; and 
laboratory work-up for connective diseases were all 
negative. Blood gas analysis showed severe hypoxemia 
without hypercapnia.
The patient was prescribed oxygen supplementation. 
In the following 18-month period, she developed 
several respiratory failure exacerbations concomitantly 
with progressive hypercapnia and bicarbonate 
retention. Clinically she developed worsening signs 
of heart failure and anasarca. The plain thoracic 
radiography showed an enlarged cardiac silhouette 
with a predominance of the right cardiac chambers. 
She became progressively restricted to bed and 
dependent on a caregiver for the essential activities 
of the daily living. She was brought to the ED for the 
sixth time after being rescued in bed with cyanosis and 
presenting altered mental status.
The physical examination revealed an ill-looking 
patient, drowsy, disoriented, cyanotic, icteric, and 
afebrile. Vital signs were characterized by blood 
pressure of 110/70 mmHg, pulse of 84 beats per 
minute, pulse oximetry of 79% with 3 L/min oxygen 
supplementation, and capillary glucose of 88 mg/dL. 
Lower limbs presented symmetric edema with skin 
hyperemia in the left leg, and the jugular veins 
were distended in the neck’s upright position. 
Heart auscultation revealed a systolic murmur in the 
tricuspid area, and crackles were detected in the lower 
left lung base. A large ascites was present hampering 
the viscera examination. The laboratory work-up 
showed normal hemoglobin determination, mild 
Figure 2. Chest CT pulmonary window — fibroemphysema. A - Centrilobular and paraseptal emphysema in the 
upper lobes; B, C and D - Indication of fibrosing interstitial lung disease characterized by ground glass opacity, areas 
of thin reticulated and also traction bronchiectasis (arrow), predominantly in the subpleural regions of the lung 
bases. A, B and C = axial plane; D = coronal plane.
Severe pulmonary hypertension due to combined pulmonary fibrosis and emphysema: another cause of death among smokers
18 Autops Case Rep (São Paulo). 2017;7(2):15-26
leukocytosis without shift to the left, thrombocytopenia, 
prolonged prothrombin time, slight renal dysfunction, 
hyponatremia, hyperbilirubinemia at the expense of 
indirect bilirubin, and elevated C-reactive protein.
Blood (four samples) and urine cultures were 
negative. The abdominal ultrasound revealed an 
average dimension and echotexture of the liver; 
and dilation of the portal vein (16 mm), inferior 
vena cava, and suprahepatic veins. The spleen was 
slightly enlarged, and a huge ascites was present. 
The echo-Doppler cardiogram showed severe dilation 
of the right cardiac chambers despite normal right 
ventricle function, and a reduced volume of the left 
ventricle. The tricuspid valve had a dilated annulus with 
severe reflux. The estimated systolic pulmonary artery 
pressure (at this time) was 76 mmHg plus the central 
venous pressure; the inferior vena cava measured 
26 mm, and the respiratory variation diameter was 
less than 50%. A non-restrictive pericardial effusion 
was present. The electrocardiogram showed a sinus 
rhythm, diffuse low-voltage complexes, and the QRS 
axis was anteriorly deviated.
The patient was treated with diuretics as well 
as antibiotic and non-invasive respiratory support. 
The heart failure, attributed to the pulmonary 
hypertension, did not improve with conventional 
therapeutic measures. The outcome was unfavorable 
with progressive neurological deterioration, acute 
renal failure, worsening thrombocytopenia, and 
enlargement of the prothrombin time. She died on 
day 7 of hospitalization in severe anasarca and due to 
respiratory failure. With the family’s informed consent 
an autopsy was performed.
AUTOPSY FINDINGS
The autopsy confirmed the general signs of 
anasarca and right cardiac failure secondary to chronic 
lung disease. Ascites was most remarkable (8 L), and 
pericardial (20 mL) and pleural effusions (200 mL each 
side) were present.
The lungs were congested and boggy (right and 
left lungs weighed 601 g and 400 g, respectively) with 
partial atelectasis. The pleural surfaces showed mild 
fibrin deposition in the upper left lobe and anthracosis. 
The upper lobes showed foci of emphysema and 
multiple grayish and fibrotic areas, which became 
more evident after formalin fixation (Figures 3 and 4). 
Histology confirmed the areas of emphysema and 
fibrosis in the upper lobes (Figure 5A), and a diffuse 
interstitial homogeneous fibrosis in the upper 
and lower lobes (Figure 5B and 5C). Interstitial 
lymphomononuclear inflammatory infiltrate was mild 
(Figure 5D). No fibroblastic foci or honeycombing was 
detected. Some larger pulmonary artery branches 
were torturous with intimal fibrosis and fibromuscular 
hyperplasia. Some arteriolar branches were markedly 
thickened (Figure 6A and 6B). A few microscopic thrombi 
Figure 3. Gross findings of lung pathology. Section of right lung showing areas of emphysema (arrow) and fibrosis 
(arrowhead).
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Figure 4. Gross findings of lung pathology. Detail of emphysematous areas.
Figure 5. Photomicrography of the lung. In A - Subpleural emphysema with airspace enlargement and fibrosis (panoramic 
view H&E 12.5X); B - Diffuse fibrosis with few alveolar spaces (H&E 12.5X); C - The alveolar septa are remarkably fibrotic 
(area of predominant peripheral fibrosis) (H&E 200X); D - Other areas showed fibrosis and mild lymphomononuclear 
inflammatory infiltrate. A tortuous and thickened pulmonary artery branch is seen (arrow) (H&E 200x).
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were detected along with areas of alveolar edema, 
hemorrhage, and hemosiderin laden macrophages 
(Figure 6C and 6D). These findings were consistent 
with previous reports of combined pulmonary fibrosis 
and emphysema (CPFE) with signs of focal thrombosis, 
and acute and previous hemorrhage.
The heart was enlarged (500 g [mean reference 
value mRV; 262g]) mostly due to enlarged right 
chambers. The right atrium showed whitish pericardial 
plaques due to non-specific fibrosis and chronic 
pericardial effusion. No atherosclerosis was detected 
in the pulmonary artery. The aorta and coronaries 
showed non-complicated atherosclerosis.
The l iver showed signs of chronic passive 
congestion with dilated veins, a nutmeg appearance 
at gross examination, centrilobular congestion, and 
necrosis. Chronic centrilobular, sinusoidal, and septal 
fibrosis was already present. Chronic congestive 
splenomegaly (293g, [mRV 112g]) was also detected at 
autopsy. Finally, signs of ischemia and necrosis related 
to systemic hypoxia and shock were detected in the 
brain, kidneys, and pancreas. The cause of death was 
interpreted as final complications of cor pulmonale 
related to pulmonary fibrosis and emphysema, with 
microscopic signs of lung thrombosis and hemorrhage.
DISCUSSION
The CPFE has become a topic of great debate 
since its first description by Cottin et al.,1 in 2005, 
as a distinct clinicopathologic entity, with unique 
Figure 6. Photomicrography of the pulmonary vascular pathology. A - Tortuous branch of pulmonary artery with 
intimal fibrosis (H&E 100X); B - Small artery with marked fibromuscular hyperplasia (H&E 400X); C - Focal pulmonary 
artery branch thrombosis (H&E 200X); D - Areas of fibrosis and hemosiderin deposition (left) and focal interstitial 
hemorrhage (right) (H&E 400X).
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clinical features, radiologic patterns, and prognosis. 
By definition, the diagnosis of emphysema has 
historically excluded the presence of fibrosis.2 In 1974, 
Auerbach et al.3 described both injuries in an autopsy 
for the first time. In 1990, Wiggins et al.4 reported a 
series of cases of fibrosing alveolitis simultaneously 
to emphysema, by CT. He also characterized reduced 
diffused lung capacity for carbon monoxide (DLCO) 
and preserved lung volumes in these patients.
The first description by Cottin et al.1 comprised 
an entity combining centrilobular or paraseptal 
emphysema in the upper lobes accompanied by 
pulmonary fibrosis in the lower lobes. Initially, patients 
with interstitial lung diseases (ILD), other than 
idiopathic pulmonary fibrosis, were excluded from the 
description. More recently, there have been reports 
of CPFE associated with other ILD, including ILD 
associated with connective tissue diseases (CTD).5-7
The prevalence of CPFE is not yet precisely 
known, ranging from 8% to 51% in patients with 
idiopathic pulmonary fibrosis (IPF).8,9 On the other 
hand, pulmonary fibrosis occurs in 4.4–8% of patients 
with emphysema.10-12 The prevalence of emphysema 
in the general population is of 21.5 cases per 1,000, 
while that of IPF is about 14-42.7 cases per 100,000.13
Patients with CPFE are mostly older males, with 
a mean age of 65 years. Cigarette smoking history 
(usually heavy smoking) is found in the vast majority 
of patients.14-16 Whether the male predominance is 
caused by greater exposure to tobacco or if gender is 
an independent risk factor for CPFE, is still uncertain.
There is a great debate whether CPFE is an 
altogether distinct entity or merely a simultaneous 
occurrence of emphysema and fibrosis in the same 
lung, as both injuries have a great causal relation with 
smoking. It is hypothesized that the resulting damage 
is determined by a genetic susceptibility and an 
environmental trigger, possibly mediated by oxidative 
stress.13,17 This oxidative stress causes cellular injury 
and apoptosis—leading to emphysema18—or cellular 
injury, activation of fibroblasts and myofibroblasts, and 
extracellular matrix deposition, resulting in pulmonary 
fibrosis.19 The resulting phenotype, then, would 
depend on the balance between apoptosis, proteolysis, 
and fibrosis.
Tobacco, via oxidative stress, is capable of 
regulating genes associated with inflammatory 
response, and genes that codify cytokines, chemokines, 
and adhesion molecules, mostly through transcription 
factors such as NF-κB and activator protein-1. 
These genes are transcribed chiefly by the histone 
acetylation, which is intensified by the reduction 
of histone deacetylase function caused by tobacco 
smoking.20 Some associated inflammation mediators 
are platelet-derived growth factor (PDGF),21 tumor 
necrosis factor alpha (TNF-α), transforming growth 
factor beta (TGF- β),22,23 and chemokine ligands 
5 (CXCL5) and 8 (CXCL8).24 The latter two are 
chemokines related to neutrophilic infiltration, which 
contribute to both emphysema and fibrosis.
CPFE is also caused by occupational exposure, 
mostly coal25 and welding,26 but also agrochemical 
compounds27 and tire manufacturing.28
A group of patients developed CPFE secondary to 
CTD, which is more frequently related to rheumatoid 
arthritis and systemic sclerosis,7 that still maintain 
associations with smoking. This particular type of 
CPFE is more commonly found among younger 
women, with milder pulmonary hypertension, minor 
impairment of the DLCO, and a less severe prognosis.
The pathological pattern of fibrosis is greatly 
varied. There have been descriptions of interstitial 
pneumonia,1 airspace enlargement with fibrosis,29 
non-specific interstitial pneumonia,1 respiratory 
bronchiolitis-associated ILD with alveolar septal 
fibrosis,30 desquamative interstitial pneumonia with 
extensive fibrosis,31 and unclassified smoking-related 
interstit ial f ibrosis.32 Our patient’s pulmonary 
pathological findings were briefly characterized by 
emphysema in the upper lobes and diffuse fibrosis 
in the entire lungs, accompanied by marked vascular 
changes consistent with pulmonary hypertension.
Studies have been showing differential patterns 
of genetic expression in CPFE. Genes associated with 
the immune system are mostly expressed in areas 
of fibrosis, whilst genes related to cellular division, 
membrane biology, and vascular biology characterize 
the expression in emphysema.33
Some reports of CPFE in non-smokers shine a 
light on possible pathways of genetic expression. 
A young non-smoking woman with CPFE was shown 
to carry a mutation in the surfactant protein C gene.34 
A young non-smoking man had CPFE possibly because 
of a mutation in the ABCA3 gene.35 Both genes are 
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associated with surfactant homeostasis and lung 
epithelial type II cells injury and death.
Another factor implicated in the pathogenesis of 
CPFE is accelerated ageing due to telomere shortening. 
Mutation of telomerase genes—namely, hTERT and 
hTR—have been reported in familial cases of CPFE. 
Telomerases are enzymes responsible for adding repeat 
sequences to telomeres. A shortening of telomeres 
possibly lowers the threshold of damage caused by 
tobacco smoking or other environmental triggers 
associated with CPFE.36-38
The preeminent symptoms in patients with CPFE, 
similarly to COPD and IPF, are cough and dyspnea. 
Among these three entities, COPD usually presents 
with a productive cough early on,39 while CPFE and 
IPF feature mainly progressive dyspnea, and cough 
with sputum may only appear in the later stages of 
the disease.40 Another key characteristic of CPFE is the 
exertion dyspnea. Other possible manifestations are 
wheezing, oral cyanosis, and asthenia. On auscultation, 
typically, “Velcro crackles” are frequently heard. 
Finger clubbing is also prevalent.41
Pulmonary arterial hypertension is severe and is 
a predictor of poor prognosis.41 Its prevalence ranges 
from 47% to 90%.42-44 Five-year survival is as low as 
25%.42 An interesting correlation exists between the 
degree of emphysema on high-resolution computed 
tomography (HRCT) and systolic pressure in the 
pulmonary artery.45 The gold standard method for 
the diagnosis of pulmonary hypertension remains 
right ventricle catheterization; however, transthoracic 
echocardiogram may be used as a screening tool.
Our patient had dyspnea as the pre-eminent 
symptom, which is characteristically progressive in 
nature. She had considerable exposure to tobacco 
during her lifetime. Cor pulmonale signs were evident, 
with lower limbs edema and congestive hepatopathy. 
This patient had an estimated pulmonary artery 
pressure of 100 mmHg, which explains the right-sided 
heart failure. The autopsy findings confirmed the 
typical findings of the pulmonary hypertension.
Characteristically, chest x-rays of CPFE patients 
are non-specific and not very useful for diagnosis or 
follow-up. The most common findings are reticulation 
in the bilateral lower lung fields and hyperlucency in the 
lung apices, corresponding to emphysematous areas.46 
The diagnosis of CPFE is based on HRCT imaging, which 
shows bilateral emphysema (mainly in the upper zones 
of the lungs) and fibrosis (mostly in the lower zones), 
with a progressive transition between emphysema and 
fibrosis.1,47 The air-space lesions include centrilobular, 
paraseptal emphysema, and bullae.48 In COPD, the 
most common pattern is centrilobular, while in CPFE 
patients paraseptal emphysema is more common and 
is supposed to be distinctive of this syndrome.17,49 
Regarding the fibrotic pattern, the usual interstitial 
pneumonia (UIP) is most commonly detected; however, 
studies have shown that the imaging findings are 
heterogeneous.50 There are reports of CPFE patients 
with HRCT showing patterns of non-specific interstitial 
pneumonia (NSIP), airspace enlargement with fibrosis 
(AEF), respiratory bronchiolitis-associated ILD (RB-ILD) 
with alveolar septal fibrosis, desquamative interstitial 
pneumonia with extensive fibrosis, and unclassifiable 
smoking-related interstitial fibrosis.50
The AEF pattern stands out as a distinct feature 
of CPFE.14,49 This pattern consists of thick-walled large 
cysts in the lower zones of the lung where reticulation 
is present. It is always associated with emphysema, 
and represents the development of pulmonary fibrosis 
in the setting of an emphysematous lung, with 
enlargement of the cysts due to retraction forces.51
Besides specific lung tissue findings, other 
CT findings for CPFE are those associated with 
pulmonary hypertension (a common finding in 
CPFE patients).45 CT scans may show dilatation of the 
central pulmonary arteries, enlargement of the right 
heart, and reduction of the peripheral branches of the 
pulmonary parenchyma.51
In our case, the CT findings showed major 
signs of pulmonary hypertension, such as pulmonary 
trunk caliber greater than the aorta, dilation of 
the right cardiac chambers, reflux of the contrast 
media into the dilated inferior vena cava and hepatic 
veins, and the presence of moderate pericardial 
effusion. The findings in lung parenchyma are also 
typical, showing paraseptal emphysema in the upper 
lobes, fibrosing ILD characterized by ground glass 
opacity (which were represented by fibrosis in the 
histological examination), thin reticulated and traction 
bronchiectasis, predominantly in the subpleural regions 
of the lung bases (a pattern associated with NSIP). 
In this case, the fibrosis findings are more remarkable 
than its emphysematous counterpart; however, both 
were present.
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Pulmonary function tests in CPFE patients are 
characterized by normal or near-normal spirometric 
values and static lung volumes, and a significant 
reduction of DLCO.1,52 This is explained by the 
cohabitation of the two types of lesions present in 
CPFE: emphysema and fibrosis. While emphysema 
causes hyperinflation, obstruction of airways, and 
greater lung compliance, fibrosis causes restrictive 
effects, traction to support the small airways and 
prevent them from collapsing, and a decrease in lung 
compliance.46 Therefore, CPFE patients have shown a 
faster decrease in forced expiratory volume in 1 second 
(FEV1)/forced vital capacity (FVC) than patients with 
IPF only, and a higher decrease in vital capacity (VC) 
and FVC compared to patients with COPD alone.53,54
The reduction in DLCO is explained by the 
reduced vascular surface area and pulmonary capillary 
blood volume, which is caused by fibrotic and 
emphysematous lesions, in combination with alveolar 
membrane thickening, which is caused by fibrotic 
lesions.47 There also seems to be a correlation 
between the different patterns on HRCT, and specific 
changes on pulmonary function tests.53 Although a 
single pulmonary function test does not seem to be 
accurate in defining the prognosis for CPFE patients, 
follow-up with annual testing appears to be useful 
in evaluating disease progression, by analyzing FEV1 
values.53 Unfortunately, our patient was not tested for 
pulmonary function because of non-compliance with 
a regular medical follow-up.
As far as we know at the date of this article, no 
particular recommendation is available regarding the 
management of patients with CPFE. It is accepted that 
measures for smoking cessation should be taken,55 
and oxygen therapy for patients with respiratory 
failure is also accepted.56,57 Vaccination for influenza 
viruses and Streptococcus pneumoniae might be also 
recommended.13 Bronchodilators might be prescribed 
in patients with a positive response to these drugs 
in pulmonary function tests.41 Recently discovered 
treatments for idiopathic pulmonary fibrosis, such as 
pirfenidone and nintedanib, might be beneficial for 
CPFE patients as well;58 however, further studies with 
CPFE patients need to be carried out to define the 
response to this particular population.59 In severe cases 
of the disease, patients should be considered for lung 
transplantation.50
Median survival for CPFE patients has been reported 
to be between 2.1 and 8.5 years. Five-year survival 
ranges between 38% and 55%.1 Progressive lung 
function tests can be used to define the prognosis 
in CPFE patients.53 In IPF patients, the annual rate of 
decline in FVC and DLCO are shown to be independent 
predictors of survival, while in patients with the 
diagnosis of CPFE the survival is strongly related to 
the decline in FEV1.53
Clinical factors for the worst prognosis in 
CPFE patients include active smoking, finger clubbing, 
and the development of pulmonary hypertension and 
lung cancer.15,60,61 Radiological examination factors take 
into account both the fibrotic and the emphysematous 
lesions. The extent of the fibrosis in the lungs seems 
to be strongly related to survival as well as the pattern 
of emphysema.15,62 Centrilobular or mixed emphysema 
had a better survival rate compared to patients with 
only IPF, and compared to CPFE patients with minor 
emphysema or advanced paraseptal emphysema.62 
The reason for these findings remains unknown, but 
they might suggest that the extent of the fibrosis is the 
most important factor in prognosis, while emphysema 
seems to only influence the survival rate in cases of 
very extensive lesions.59
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